acetic acid;2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: acetic acid;2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
• 化学式: C28H32ClNO3
• 分子量: 466.0
• InChiKey: MPARJSSUXBIRHY-OQKDUQJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.31
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• SOLUBLE COMPOSITIONS OF TOREMIFENE
  申请人：ORION CORPORATION

  公开号：EP1140197B1

  公开（公告）日：2004-04-28
• US6491951B1
  申请人：——

  公开号：US6491951B1

  公开（公告）日：2002-12-10
• [EN] SOLUBLE COMPOSITIONS OF TOREMIFENE<br/>[FR] COMPOSITIONS SOLUBLES DE TOREMIFENE
  申请人：ORION CORP

  公开号：WO2000035486A1

  公开（公告）日：2000-06-22

  The invention relates to aqueous composition of toremifene or a pharmaceutically acceptable salt thereof comprises lactic acid, acetic acid, formic acid, methanesulfonic acid or the corresponding anion (lactate, acetate, formate or mesylate) as a solubility enhancing agent. The invention also relates to novel salts of toremifene with an acid selected from the group consisting of lactic acid, acetic acid, formic acid or methanesulfonic acid.
• [EN] METHOD FOR HORMONE ABLATIVE THERAPY INDUCED OSTEOPOROSIS<br/>[FR] MÉTHODE DE LUTTE CONTRE L'OSTÉOPOROSE INDUITE PAR UNE HORMONOTHÉRAPIE SUPPRESSIVE
  申请人：GTX INC

  公开号：WO2011085303A1

  公开（公告）日：2011-07-14

  This invention relates to treatment, reducing the incidence, inhibition, suppression, prevention of hormone ablation therapy induced bone related disorders such as osteoporosis, osteopenia, increased bone resorption, bone fracture, bone frailty, loss of bone mineral density (BMD), or any combination thereof in women suffering from breast cancer by administering about 120 mg of toremifene citrate.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DU CANCER
  申请人：PELLFICURE PHARMACEUTICALS INC

  公开号：WO2018195202A1

  公开（公告）日：2018-10-25

  Disclosed herein pharmaceutical compositions that include a compound of Formula (I) in combination with a cancer therapy treatment, such as a taxane-based chemotherapeutic or a platinum-based antineoplastic agent and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as bladder cancer or prostate cancer with such combinations of a compound of Formula (I) and a cancer therapy treatment.